Prestige Consumer Healthcare (NYSE:PBH) Upgraded by StockNews.com to Buy Rating

StockNews.com upgraded shares of Prestige Consumer Healthcare (NYSE:PBH) from a hold rating to a buy rating in a research report sent to investors on Saturday.

A number of other equities analysts have also recently issued reports on PBH. Oppenheimer upped their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a report on Thursday, February 13th. Royal Bank of Canada upgraded Prestige Consumer Healthcare to a “hold” rating in a report on Thursday, May 8th. DA Davidson upped their price objective on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Finally, Canaccord Genuity Group upped their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Prestige Consumer Healthcare presently has an average rating of “Moderate Buy” and a consensus price target of $93.33.

Prestige Consumer Healthcare Price Performance

Prestige Consumer Healthcare stock opened at $89.01 on Friday. Prestige Consumer Healthcare has a 52 week low of $62.35 and a 52 week high of $90.04. The business has a 50-day simple moving average of $83.37 and a 200 day simple moving average of $82.04. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The stock has a market cap of $4.40 billion, a price-to-earnings ratio of 20.85, a PEG ratio of 2.69 and a beta of 0.44.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The business had revenue of $296.52 million during the quarter, compared to analysts’ expectations of $289.36 million. During the same period in the previous year, the business earned $1.02 earnings per share. The firm’s revenue was up 7.0% on a year-over-year basis. On average, research analysts forecast that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Mary Beth Fritz sold 1,678 shares of the business’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the sale, the senior vice president now owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. The trade was a 8.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC lifted its stake in shares of Prestige Consumer Healthcare by 204.0% in the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock valued at $9,010,000 after acquiring an additional 70,330 shares during the last quarter. United Services Automobile Association bought a new position in Prestige Consumer Healthcare during the 1st quarter valued at approximately $277,000. Aristeia Capital L.L.C. bought a new position in Prestige Consumer Healthcare during the 1st quarter valued at approximately $412,000. Goldman Sachs Group Inc. raised its position in Prestige Consumer Healthcare by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock valued at $46,997,000 after purchasing an additional 120,965 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Prestige Consumer Healthcare by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock valued at $2,535,000 after purchasing an additional 1,289 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.